TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14514368

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (Group B)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Surgical operation only (Group A)
Number of subjects: 372
Study: 11192518

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate supplementation (1 mg/kg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 16
Study: 9355191

Group type: EXPERIMENTAL
Intervention: Cannulated vitrectomy system
Number of subjects: 77

Group type: COMPARATOR
Intervention: Noncannulated group
Number of subjects: 77
Study: 8472516

Group type: EXPERIMENTAL
Intervention: Tablets (600 mg of ST‐679)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Envelopes (600 mg of ST‐679)
Number of subjects: 0
Study: 2433901

Group type: EXPERIMENTAL
Intervention: Dextran 40 (500 ml on admission and on days 1 and 2; 250 ml on days 4 and 6)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no dextran or venesection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 29943239

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at individual alpha peak frequency (1.5 mA for 10 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26610167

Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy (DET)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 141
Study: 24987174

Group type: EXPERIMENTAL
Intervention: Oral sildenafil 25 mg, administered eight hourly for 24 hours before surgery (N = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (N = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral sildenafil 25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22570428

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg taken up to 3 times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 50
Study: 19890257

Group type: EXPERIMENTAL
Intervention: Psychosocial stressor (Trier social stress test (TSST))
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 102

Group type: COMPARATOR
Intervention: Beta-adrenoceptor antagonist propranolol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cortisol with propranolol, cortisol alone, or propranolol alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Stress or cortisol
Number of subjects: 102
Study: 18806024

Group type: EXPERIMENTAL
Intervention: Intranasal remifentanil (4 mcg/kg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 188
Study: 15664480

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (2000/125 mg), given twice daily
Number of subjects: 351

Group type: COMPARATOR
Intervention: Conventional amoxicillin/clavulanate formulations (control)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (2000/125 mg) for PRSP-infected patients
Number of subjects: 351
Study: 12092689

Group type: EXPERIMENTAL
Intervention: Active therapy (twice daily insulin injections plus an annual insulin infusion)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Close observation
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 339
Study: 10048236

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) with intensive diabetes management
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intensive diabetes management without CST
Number of subjects: 77
Study: 7479201

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (1-g intravenous dose of cefotaxime plus 500-mg oral dose of metronidazole)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cefoxitin (2 g intravenous doses every 6 hours)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (3 g intravenous doses every 6 hours)
Number of subjects: 9
Study: 2185526

Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 0
Study: 91837

Group type: EXPERIMENTAL
Intervention: 99mTc‐pyridoxylidene glutamate (PG) scanning
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oral cholecystography
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 116
Study: 28817412

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bodyflow (BF) therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Deep oscillation (DO) therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 27712462

Group type: EXPERIMENTAL
Intervention: Access therapy with PRF and 1% ALN gel (group 3)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Access therapy alone (group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Access therapy with PRF (group 2)
Number of subjects: 72
Study: 25565583

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 300 mg/d)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 23788068

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 16
Study: 21377074

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 50
Study: 19418780

Group type: EXPERIMENTAL
Intervention: Community leg ulcer clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home care visits
Number of subjects: 0
Study: 17364153

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal patch (TAPP) procedure
Number of subjects: 147

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 147
Study: 15383196

Group type: EXPERIMENTAL
Intervention: Dose 1 frovatriptan
Number of subjects: 241

Group type: COMPARATOR
Intervention: Dose 1 placebo
Number of subjects: 241
Study: 14568602

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interferon alpha‐2b/ribavirin
Number of subjects: 20
Study: 10103339

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy (4 mg/kg every 12 hours for 6 weeks, then 8 mg/kg every 12 hours for 6 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Abacavir in combination with another antiretroviral agent (8 mg/kg every 12 hours for 12 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Abacavir monotherapy
Number of subjects: 47
Study: 7758213

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (2.8 micrograms of sodium selenite per kg per day) for 5 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo control for 5 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Selenium supplementation and Placebo control
Number of subjects: 27
Study: 2108254

Group type: EXPERIMENTAL
Intervention: Na2 ethylene diamine tetra acetic acid (EDTA) plus MgSO4, B complex, and vitamin C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo of MgSO4, B complex, and vitamin C in Ringer's lactate solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EDTA after initial placebo treatment
Number of subjects: 10
Study: 44182

Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 0
Study: 31714582

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 134
Study: 30646801

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2170

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2170

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2170
Study: 28910196

Group type: EXPERIMENTAL
Intervention: Alpinia galanga proprietary extract (E-AG-01)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combination of Alpinia galanga (E-AG-01) with caffeine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 26017535

Group type: COMPARATOR
Intervention: FroDex 37.5 (early intake)
Number of subjects: 314

Group type: COMPARATOR
Intervention: FroDex 37.5 (late intake)
Number of subjects: 314

Group type: COMPARATOR
Intervention: FroDex 25 (early intake)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Frova (early intake)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Frova (late intake)
Number of subjects: 314
Study: 24322060

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407
Study: 22801247

Group type: COMPARATOR
Intervention: Triple oral therapy (metformin, glyburide, and pioglitazone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin and metformin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin and metformin (initial therapy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both treatment groups (triple oral therapy and insulin/metformin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin-based treatment
Number of subjects: 16
Study: 20021599

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness meditation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: 8-week education control program
Number of subjects: 40
Study: 18090191

Group type: EXPERIMENTAL
Intervention: Symptom management (SM) intervention
Number of subjects: 40
Study: 15141793

Group type: COMPARATOR
Intervention: Bag-valve device
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Oxylator (manual and automatic modes)
Number of subjects: 104
Study: 11226823

Group type: EXPERIMENTAL
Intervention: Lanfast (Julphar, UAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lanzor (Laboratoires Houde, Paris, France)
Number of subjects: 0
Study: 9541446

Group type: EXPERIMENTAL
Intervention: Fucithalmic single unit dose eye drops
Number of subjects: 144

Group type: COMPARATOR
Intervention: Chloramphenicol eye ointment
Number of subjects: 144
Study: 8031107

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) using a pacifier immediately after crying was induced by a heelstick.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (ONNS) infants who did not receive NNS.
Number of subjects: 59
Study: 31553201

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29146604

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 32
Study: 25371402

Group type: EXPERIMENTAL
Intervention: Health management program
Number of subjects: 8217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8217
Study: 24148616

Group type: EXPERIMENTAL
Intervention: IV 3% saline
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral 3% saline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 26
Study: 23062548

Group type: EXPERIMENTAL
Intervention: rHFSC (recombinant human hyaluronidase-facilitated subcutaneous rehydration)
Number of subjects: 148

Group type: COMPARATOR
Intervention: IV (intravenous rehydration)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: rHFSC
Number of subjects: 148

Group type: COMPARATOR
Intervention: IV
Number of subjects: 148
Study: 19541916

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AEX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Stretching Exercise (SE)
Number of subjects: 38
Study: 17122613

Group type: EXPERIMENTAL
Intervention: Early laparoscopy (LAP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Clinical observation (OBS)
Number of subjects: 135
Study: 15275765

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oxazepam 15 mg (active placebo)
Number of subjects: 120
Study: 11420167

Group type: EXPERIMENTAL
Intervention: High dose aprotinin (20,000 IU/kg as pretreatment followed by 7500 IU/kg for 6 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose aprotinin
Number of subjects: 20
Study: 9240302

Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass (36 degrees C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cold cardiopulmonary bypass (28 degrees C)
Number of subjects: 62
Study: 12959274

Group type: EXPERIMENTAL
Intervention: BRL 35135 8 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (N20) + BRL 35135 8 mg
Number of subjects: 8
Study: 3549173

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 1.0 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 0.5 mg to 3.0 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate >1.0 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate (general)
Number of subjects: 6
Study: 27402135

Group type: EXPERIMENTAL
Intervention: PocketCPR application
Number of subjects: 118
Study: 27089542

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX) treatment with calf muscle injections every 6 months if needed
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative treatment (CO) consisting of firm shoes, night splints, home stretching program, and physiotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conservative treatment (CO)
Number of subjects: 30
Study: 24225356

Group type: EXPERIMENTAL
Intervention: 6-month lipid-based nutrient supplement (LNS) providing 108 kcal and other nutrients including vitamin A, vitamin B-12, iron, and zinc at ≥80% of the recommended amounts
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: 3-month lipid-based nutrient supplement (LNS)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 589
Study: 21869764

Group type: EXPERIMENTAL
Intervention: Caloric restricted diet with resistance training (RT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Caloric restricted diet without resistance training (RT)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bertin index (DXA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Bertin index and CT scan
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fat mass and lean body mass
Number of subjects: 92
Study: 20684825

Group type: EXPERIMENTAL
Intervention: Statin treatment after PCI
Number of subjects: 238

Group type: COMPARATOR
Intervention: Hypo-adiponectinemia at baseline
Number of subjects: 238
Study: 18155287

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online Transtheoretical Model (TTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Risk Intervention (HRI)
Number of subjects: 0
Study: 15774905

Group type: EXPERIMENTAL
Intervention: High saturated fat (SFA) diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (CARB) diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: High monounsaturated fat (MUFA) diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: High polyunsaturated fat (PUFA) diet
Number of subjects: 40
Study: 14629243

Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg per day, with increments to a maximum of 100 mg per day)
Number of subjects: 36
Study: 10622518

Group type: EXPERIMENTAL
Intervention: Morning trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evening trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Average minimum intensity
Number of subjects: 20
Study: 7795149

Group type: EXPERIMENTAL
Intervention: 4 g fish-oil concentrate per day
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group (no fish oil)
Number of subjects: 511
Study: 2029123

Group type: EXPERIMENTAL
Intervention: Pediazole (ES) - 50 mg/kg + 150 mg/kg sulfamide, given in three divided doses for ten days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cefaclor - 40-50 mg/kg, given in three divided doses for ten days
Number of subjects: 106
Study: 7025475

Group type: EXPERIMENTAL
Intervention: Benzafibrate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 29
Study: 31235418

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering (target LDL-C <70mg/dL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional lipid lowering (target LDL-C ≥70mg/dL, <128mg/dL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional lipid lowering
Number of subjects: 150
Study: 30372084

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg IR tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiological variables (pH and postdose phase III contractions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Statistical analysis of plasma profiles
Number of subjects: 20
Study: 26686818

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Parents' perceived behavioral control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adolescents' subjective norms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intention to limit SSB consumption
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TPB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adolescents' intention to limit SSB consumption
Number of subjects: 100
Study: 24841265

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 10030

Group type: COMPARATOR
Intervention: Non-chlorhexidine groups
Number of subjects: 10030

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-resistant isolates
Number of subjects: 10030
Study: 22191994

Group type: EXPERIMENTAL
Intervention: Tongue-holding swallow (THS) group (THSG) performed the tongue‐holding manoeuvre every 5s for 20min for 20 sessions over 4 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal swallow group (control) swallowed without tongue‐holding for the same length of time.
Number of subjects: 20
Study: 20589148

Group type: EXPERIMENTAL
Intervention: Warfarin treatment for thromboembolic complications
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Warfarin treatment for haemorrhagic complications
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (matched controls for thromboembolic complications)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (matched controls for haemorrhagic complications)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haemorrhagic cases
Number of subjects: 63
Study: 17342693

Group type: EXPERIMENTAL
Intervention: Vitamin B 12 for two months followed by folic acid for two months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Folic acid for two months followed by Vitamin B 12 for two months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Washout period after treatment
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: End of study measurements
Number of subjects: 74
Study: 14665555

Group type: EXPERIMENTAL
Intervention: 500 ml of gelatin colloid solution intravenously before surgery
Number of subjects: 396

Group type: COMPARATOR
Intervention: Conventional i.v. fluid regime with a crystalloid solution (saline)
Number of subjects: 396
Study: 11703374

Group type: EXPERIMENTAL
Intervention: HAART with plasma HIV-1 RNA suppressed to below 500 copies/ml (group 1)
Number of subjects: 355

Group type: COMPARATOR
Intervention: HAART with at least one viral rebound (group 2)
Number of subjects: 355
Study: 9204846

Group type: COMPARATOR
Intervention: Clean dressing technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile dressing technique
Number of subjects: 30
Study: 7703514

Group type: EXPERIMENTAL
Intervention: Ileo-rectal anastomosis (IRA)
Number of subjects: 74
Study: 3295629

Group type: EXPERIMENTAL
Intervention: Frozen section examinations on axillary lymph nodes
Number of subjects: 162
Study: 29365294

Group type: EXPERIMENTAL
Intervention: Solanezumab (400 mg, intravenously every 4 weeks for 76 weeks)
Number of subjects: 2129

Group type: COMPARATOR
Intervention: Placebo (intravenously every 4 weeks for 76 weeks)
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 2129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2129
Study: 26513202

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (fixed dose 75 mg/day)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (flexible dose 75-225 mg/day)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (fixed dose)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (flexible dose)
Number of subjects: 538
Study: 23965396

Group type: EXPERIMENTAL
Intervention: BMS-927711 75 mg
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: BMS-927711 150 mg
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: BMS-927711 300 mg
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: BMS-927711 (25-600 mg)
Number of subjects: 885
Study: 22467840

Group type: EXPERIMENTAL
Intervention: Younger individuals (20-59 years old)
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Older individuals (60 years and older)
Number of subjects: 1541
Study: 20400912

Group type: EXPERIMENTAL
Intervention: Pantoprazole 1.2 mg/kg/day for 4 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 17910747

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus hydrochlorothiazide 12.5 mg (T/HCTZ)
Number of subjects: 840
Study: 16260435

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST) for 6 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 31